FDA Actions Neutral 6

Inovio Faces Regulatory Hurdle for INO-3107 Amid Q4 Earnings and Cash Burn

Inovio (INO) reports FDA acceptance of its BLA for INO-3107 with a PDUFA date of October 30, 2026, though preliminary regulatory concerns regarding accelerated approval eligibility persist. Meanwhile, the company continues to manage a narrowing cash runway as it pivots toward commercialization.

· 1 min read · By Biotech Intelligence Brief

Beat this week

Last 7 days · FDA Actions

5 stories
6 avg impact
0% positive
20% negative
vs prior 7 days +4 +4 stories vs prior 7 days

Impact 6.0/10 (+1 vs prior). Counts are stories in our record, not a market forecast.

Open the change report

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 20 percentage points.

  • 80% neutral
  • 20% negative

This story sits in FDA Actions — the counts compare this beat's last 7 days with the previous 7 in our verified record, not a market forecast.

Figures are computed live from our source-verified story record (as of ) The volume change compares this window with the prior 7 days in the same record. — see our methodology for how impact and sentiment are derived.

Share

Biotech briefing

Key takeaways

6 impact
Neutralsentiment
1min read
  1. Inovio (INO) reports FDA acceptance of its BLA for INO-3107 with a PDUFA date of October 30, 2026, though preliminary regulatory concerns regarding accelerated approval eligibility persist.
  2. Meanwhile, the company continues to manage a narrowing cash runway as it pivots toward commercialization.

Cite This Page

"Inovio Faces Regulatory Hurdle for INO-3107 Amid Q4 Earnings and Cash Burn." Biotech Intelligence Brief, March 18, 2026. https://getbiobrief.com/story/inovio-ino-3107-fda-accelerated-approval-concerns

Related Stories

FDA Actions

FDA Clears 3 Updated COVID Shots as XFG/Stratus Dominates

The FDA has cleared updated COVID-19 vaccines from Pfizer, Moderna, and Novavax for 2026-27, targeting the XFG/Stratus strain. The decision resets the competitive landscape for seasonal vaccine makers.

FDA Actions

3 in 5 abortions use mifepristone as 5th Circuit weighs limits

For biopharma, the dispute over mifepristone prescribing rules is a test of FDA regulatory authority over an approved drug's risk evaluation and mitigation strategy. The case may influence how drug safety restrictions are litigated and how federal preemption applies to medication abortion.

FDA Actions

FDA Drug Chief to Oversee 3 Psychedelic Candidates: Psilocybin, MDMA, LSD

A former psychiatric drug regulator with psychedelic nonprofit experience now leads FDA's drug center as Trump and RFK push faster reviews. Biopharma teams should watch psilocybin, MDMA and LSD programs plus the new vaccines center director.

FDA Actions

FDA Names 4 Center Directors as Psychedelics Reviews Take Shape

The FDA's new permanent CDER director is Michael Davis, whose psychiatric drug and psychedelic nonprofit background aligns with White House calls for faster psilocybin, MDMA, and LSD reviews. Vaccine and tobacco center leadership also stabilized.

How we covered this story

Every story in our biotech coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.

Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the biotech space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.

Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.

See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.

Signal on this pageWhat it tells you
Verified by N sourcesIndependent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly.
Impact score (1-10)Regulatory + financial + operational weight. 8+ signals an experienced-operator action item.
SentimentFive-tier classification trained on labeled biotech-specific corpora.
TimelineWhere applicable, the related-events sequence that contextualizes today's development.